Fredrick F. Van Goor,William Lawrence Burton,Chien-Jung Huang,Paul Adrian Negulescu,Haihui Yu
申请号：
US13681110
公开号：
US20130331412A9
申请日:
2012.11.19
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
